CXCR4 and ovarian neoplasm: We have recently demonstrated that the innate resistance properties of highly metastatic ovarian tumors, together with the tumor immunosuppressive network, could be overcome by the oncolytic vaccinia virus (OVV)-delivered CXCR4 antagonist (CXCR4-A), which was particularly effective in combination with doxorubicin-mediated killing.8